ARCHIVES

Group Chairs Urge NCI to Limit Authority of Steering Committees That Determine Which Trials Get Funded

This article is from The Cancer Letter archive.

Vol. 37 No. 31 | August 5, 2011

Download PDF Visit The Full Archive

Related Articles

Montana Drug Salesman Pleads Guilty to Selling Counterfeit Avastin

July 25, 2013

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

August 26, 2005

In Brief: Final appropriations for NCI Still Probably $875 Million; US-USR Drug Book Available

July 1, 1977

Tobacco Council Announces 11 New Grant Awards

January 24, 1975

Guest Editorial: Even Slam-Dunk Applications Can Benefit From Public Scrutiny and Discussion at ODAC

August 10, 2012

FDA Pettiness Holds Up Trials with Promising Anticancer Drugs

November 14, 1975